179 related articles for article (PubMed ID: 19911377)
1. Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes.
Zhang X; Frezza M; Milacic V; Ronconi L; Fan Y; Bi C; Fregona D; Dou QP
J Cell Biochem; 2010 Jan; 109(1):162-172. PubMed ID: 19911377
[TBL] [Abstract][Full Text] [Related]
2. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
Milacic V; Chen D; Ronconi L; Landis-Piwowar KR; Fregona D; Dou QP
Cancer Res; 2006 Nov; 66(21):10478-86. PubMed ID: 17079469
[TBL] [Abstract][Full Text] [Related]
3. Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.
Nardon C; Schmitt SM; Yang H; Zuo J; Fregona D; Dou QP
PLoS One; 2014; 9(1):e84248. PubMed ID: 24392119
[TBL] [Abstract][Full Text] [Related]
4. New comprehensive studies of a gold(III) Dithiocarbamate complex with proven anticancer properties: Aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway.
Tomasello MF; Nardon C; Lanza V; Di Natale G; Pettenuzzo N; Salmaso S; Milardi D; Caliceti P; Pappalardo G; Fregona D
Eur J Med Chem; 2017 Sep; 138():115-127. PubMed ID: 28651154
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts.
Cattaruzza L; Fregona D; Mongiat M; Ronconi L; Fassina A; Colombatti A; Aldinucci D
Int J Cancer; 2011 Jan; 128(1):206-15. PubMed ID: 20209498
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Chen D; Landis-Piwowar KR; Chen MS; Dou QP
Breast Cancer Res; 2007; 9(6):R80. PubMed ID: 18300387
[TBL] [Abstract][Full Text] [Related]
8. Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.
Quero J; Cabello S; Fuertes T; Mármol I; Laplaza R; Polo V; Gimeno MC; Rodriguez-Yoldi MJ; Cerrada E
Inorg Chem; 2018 Sep; 57(17):10832-10845. PubMed ID: 30117739
[TBL] [Abstract][Full Text] [Related]
9. Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes.
Ronconi L; Aldinucci D; Dou QP; Fregona D
Anticancer Agents Med Chem; 2010 May; 10(4):283-92. PubMed ID: 20184554
[TBL] [Abstract][Full Text] [Related]
10. Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.
Cvek B; Milacic V; Taraba J; Dou QP
J Med Chem; 2008 Oct; 51(20):6256-8. PubMed ID: 18816109
[TBL] [Abstract][Full Text] [Related]
11. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.
Saggioro D; Rigobello MP; Paloschi L; Folda A; Moggach SA; Parsons S; Ronconi L; Fregona D; Bindoli A
Chem Biol; 2007 Oct; 14(10):1128-39. PubMed ID: 17961825
[TBL] [Abstract][Full Text] [Related]
12. Molecular study on copper-mediated tumor proteasome inhibition and cell death.
Xiao Y; Chen DI; Zhang X; Cui Q; Fan Y; Bi C; Dou QP
Int J Oncol; 2010 Jul; 37(1):81-87. PubMed ID: 20514399
[TBL] [Abstract][Full Text] [Related]
13. Chemical biology of anticancer gold(III) and gold(I) complexes.
Zou T; Lum CT; Lok CN; Zhang JJ; Che CM
Chem Soc Rev; 2015 Dec; 44(24):8786-801. PubMed ID: 25868756
[TBL] [Abstract][Full Text] [Related]
14. Insights into the reactivity of gold-dithiocarbamato anticancer agents toward model biomolecules by using multinuclear NMR spectroscopy.
Boscutti G; Marchiò L; Ronconi L; Fregona D
Chemistry; 2013 Sep; 19(40):13428-36. PubMed ID: 24038383
[TBL] [Abstract][Full Text] [Related]
15. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".
Yang H; Shi G; Dou QP
Mol Pharmacol; 2007 Feb; 71(2):426-37. PubMed ID: 17093135
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer.
Gambini V; Tilio M; Maina EW; Andreani C; Bartolacci C; Wang J; Iezzi M; Ferraro S; Ramadori AT; Simon OC; Pucciarelli S; Wu G; Dou QP; Marchini C; Galassi R; Amici A
Eur J Med Chem; 2018 Jul; 155():418-427. PubMed ID: 29906688
[TBL] [Abstract][Full Text] [Related]
17. Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells.
Milacic V; Jiao P; Zhang B; Yan B; Dou QP
Int J Oncol; 2009 Dec; 35(6):1481-91. PubMed ID: 19885572
[TBL] [Abstract][Full Text] [Related]
18. New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.
Altaf M; Monim-Ul-Mehboob M; Kawde AN; Corona G; Larcher R; Ogasawara M; Casagrande N; Celegato M; Borghese C; Siddik ZH; Aldinucci D; Isab AA
Oncotarget; 2017 Jan; 8(1):490-505. PubMed ID: 27888799
[TBL] [Abstract][Full Text] [Related]
19. The proteasome is a molecular target of environmental toxic organotins.
Shi G; Chen D; Zhai G; Chen MS; Cui QC; Zhou Q; He B; Dou QP; Jiang G
Environ Health Perspect; 2009 Mar; 117(3):379-86. PubMed ID: 19337512
[TBL] [Abstract][Full Text] [Related]
20. Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities.
Micale N; Schirmeister T; Ettari R; Cinellu MA; Maiore L; Serratrice M; Gabbiani C; Massai L; Messori L
J Inorg Biochem; 2014 Dec; 141():79-82. PubMed ID: 25217719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
